It appears their cash flow burn rate can be held t
Post# of 72447
(Total Views: 312)
Posted On: 06/29/2017 10:35:05 AM
It appears their cash flow burn rate can be held to approximately $1M/month with current R&D staff and programs.
A phase 2b for B-UP will need to be randomized double-blind as opposed to a cheap small proof of concept as just conducted.
A Prurisol phase 3 will need to be randomized double-blind and large enough to be NDA worthy statistically bullet-proof.
Either of these would be north of $30M IMO, as would the Brilacidin ABSSSI p3. We are into the shelf funding.
Kevetrin will pose more expensive mid-stage and late-stage trials as CRO and clinical costs will involve much more extensive data and enrollment - and must be statistically strong (e.g. overall survival, progression, p53 data, etc.) to be of value. Expensive.
The $46M shelf also represents a nearly 30% dilution at current market cap and would fund one phase 3, which would be a justifiable means of financing it. The Aspire funding and cash on-hand will keep the lights on and perhaps fund another phase 2 proof of concept, but it doesn't advance the ball very much.
The point is, without the right partnership, they will be left treading water by this time next year. This is largely why the stock price is still sitting down here although many attribute it to manipulation, Mako, etc. They have driven it down, but too few are jumping back in.
Now the more likely story. . . the stock is a steal at this price as IPIX is actively seeking a partnership, presumably there is interest, and two of the pipeline candidates are mid-stage ripe - Brilacidin UP, OM and Prurisol. IMO Kevetrin remains a leap for a pharma until the picture is clear with the higher dosing regimen.
A phase 2b for B-UP will need to be randomized double-blind as opposed to a cheap small proof of concept as just conducted.
A Prurisol phase 3 will need to be randomized double-blind and large enough to be NDA worthy statistically bullet-proof.
Either of these would be north of $30M IMO, as would the Brilacidin ABSSSI p3. We are into the shelf funding.
Kevetrin will pose more expensive mid-stage and late-stage trials as CRO and clinical costs will involve much more extensive data and enrollment - and must be statistically strong (e.g. overall survival, progression, p53 data, etc.) to be of value. Expensive.
The $46M shelf also represents a nearly 30% dilution at current market cap and would fund one phase 3, which would be a justifiable means of financing it. The Aspire funding and cash on-hand will keep the lights on and perhaps fund another phase 2 proof of concept, but it doesn't advance the ball very much.
The point is, without the right partnership, they will be left treading water by this time next year. This is largely why the stock price is still sitting down here although many attribute it to manipulation, Mako, etc. They have driven it down, but too few are jumping back in.
Now the more likely story. . . the stock is a steal at this price as IPIX is actively seeking a partnership, presumably there is interest, and two of the pipeline candidates are mid-stage ripe - Brilacidin UP, OM and Prurisol. IMO Kevetrin remains a leap for a pharma until the picture is clear with the higher dosing regimen.
(1)
(2)